LA JOLLA PHARMACEUTICAL CO Form 425 March 01, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

March 1, 2010

La Jolla Pharmaceutical Company

(Exact name of registrant as specified in its charter)

Delaware	0-24274	33-0301283
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employe Identification No
4365 Executive Drive, Suite 300, San Diego, California		92121
(Address of principal executive offices)		(Zip Code)
Registrant s telephone number, including area code:		(858) 452-6600
	Not Applicable	
Former name	or former address, if changed since	last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- $[x] \ \ Written \ communications \ pursuant \ to \ Rule \ 425 \ under \ the \ Securities \ Act \ (17 \ CFR \ 230.425)$
- [] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- [] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top	of t	the	Form	i
Item	8.0)1 (Other	Events.

On March 1, 2010, La Jolla Pharmaceutical Company issued a press release providing details concerning the adjournment of its special meeting of stockholders initially held on February 26, 2010. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. 99.1 Press Release Dated March 1, 2010.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

La Jolla Pharmaceutical Company

March 1, 2010 By: /s/ Gail A. Sloan

Name: Gail A. Sloan

Title: Vice President of Finance and Secretary

Top of the Form

Exhibit Index

Exhibit No.	Description	
99.1	Press Release Dated March 1, 2010.	